Ameriprise Financial Inc. Has $23.04 Million Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)

Ameriprise Financial Inc. boosted its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 17.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,547,591 shares of the company's stock after buying an additional 228,325 shares during the quarter. Ameriprise Financial Inc. owned 1.69% of Arcus Biosciences worth $23,044,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. R Squared Ltd purchased a new stake in Arcus Biosciences during the fourth quarter valued at about $26,000. US Bancorp DE lifted its stake in Arcus Biosciences by 2,432.0% during the fourth quarter. US Bancorp DE now owns 6,887 shares of the company's stock valued at $103,000 after buying an additional 6,615 shares in the last quarter. PEAK6 LLC purchased a new stake in Arcus Biosciences during the fourth quarter valued at about $149,000. AXQ Capital LP purchased a new stake in Arcus Biosciences in the 4th quarter worth about $160,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in Arcus Biosciences in the 4th quarter worth about $207,000. Institutional investors own 92.89% of the company's stock.

Insider Activity at Arcus Biosciences

In other Arcus Biosciences news, Director Yasunori Kaneko purchased 20,000 shares of the company's stock in a transaction on Thursday, February 27th. The shares were bought at an average cost of $10.06 per share, with a total value of $201,200.00. Following the transaction, the director now directly owns 28,400 shares in the company, valued at approximately $285,704. This represents a 238.10% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Terry J. Rosen purchased 19,800 shares of the company's stock in a transaction on Thursday, February 27th. The stock was acquired at an average cost of $10.18 per share, for a total transaction of $201,564.00. Following the completion of the transaction, the chief executive officer now owns 2,554,160 shares in the company, valued at approximately $26,001,348.80. This trade represents a 0.78% increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

RCUS has been the subject of several research analyst reports. HC Wainwright raised Arcus Biosciences from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $18.00 to $24.00 in a research note on Wednesday, February 26th. Wedbush reaffirmed an "outperform" rating and set a $33.00 price target on shares of Arcus Biosciences in a research note on Wednesday, May 7th. Bank of America cut their price target on Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a research note on Wednesday, February 19th. Wells Fargo & Company cut their price target on Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Finally, The Goldman Sachs Group cut their price target on Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Arcus Biosciences presently has an average rating of "Moderate Buy" and an average price target of $25.67.

Arcus Biosciences Stock Performance

Shares of RCUS stock traded down $0.01 during trading on Friday, reaching $8.56. The company had a trading volume of 920,596 shares, compared to its average volume of 840,805. The firm's 50 day simple moving average is $8.28 and its two-hundred day simple moving average is $12.11. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. Arcus Biosciences, Inc. has a one year low of $6.50 and a one year high of $18.98. The company has a market capitalization of $906.38 million, a PE ratio of -2.72 and a beta of 0.88.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($1.14) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.12). Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The company had revenue of $28.00 million during the quarter, compared to the consensus estimate of $38.61 million. During the same period in the previous year, the business posted ($0.05) earnings per share. The firm's revenue was down 80.7% on a year-over-year basis. Sell-side analysts forecast that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.